Today: 20 January 2026
Subscribe
Browse Category

Drug Pricing News 30 October 2025 - 11 November 2025

Novo Nordisk (NVO) Slashes Wegovy Price in India Up to 37% as Board Vote Nears; U.S. Access Deal Sets 2026 Shift — Nov. 11, 2025

Novo Nordisk (NVO) Slashes Wegovy Price in India Up to 37% as Board Vote Nears; U.S. Access Deal Sets 2026 Shift — Nov. 11, 2025

Novo Nordisk cuts Wegovy prices in India up to 37% and faces a pivotal board vote this week, as a U.S. pricing/access deal looms for 2026. Date: November 11, 2025 Key takeaways India: Wegovy gets markedly cheaper — and it’s about more than price Novo Nordisk cut Wegovy’s Indian list prices across the dose range, with the monthly 2.4 mg…
11 November 2025
···
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Pops as White House Strikes Obesity-Drug Pricing Deal; New 20% Weight‑Loss Data Fuels Momentum — Today, November 6, 2025

Eli Lilly stock today: drivers, numbers, and what to watch for next. Key takeaways (Nov 6, 2025) Eli Lilly stock today: quote & range As of this afternoon, LLY traded near $935.89, up about 1.1%, with today’s range $916.37–$949.90 and a 52‑week range $624.00–$955.43 (values delayed up to 15 minutes). Reuters 1) The White House’s obesity‑drug deal: lower prices, broader…
6 November 2025
··
Pfizer Stock Soars: Trump’s Drug-Price Deal and $7B Weight-Loss Bet Spark Rally

Pfizer Stock Soars: Trump’s Drug-Price Deal and $7B Weight-Loss Bet Spark Rally

Stock Price & Recent Performance Pfizer’s stock has been rangebound in the low-to-mid $20s for much of 2025. By late September, PFE traded around $23.60 – about 9% below its price a year earlier ts2.tech – as investors grappled with the end of Covid vaccine and treatment revenues. That all changed in early October. In the final trading week of…
30 October 2025
···
1 2 3 4

Stock Market Today

  • Chipotle Stock Forecast 2026-2030: Challenges, Growth, and Market Outlook
    January 20, 2026, 10:06 AM EST. Chipotle Mexican Grill (NYSE: CMG) lowered its full-year same-store sales forecast, citing shifts in consumer spending, which led to a nearly 20% stock decline to a 52-week low of $29.75. Shares are down 25.9% over six months, lagging the S&P 500, though Wall Street analysts maintain a bullish stance with an average buy recommendation and an 11% upside target for the next year. The company faces pressures from inflation, high food costs, and rising labor expenses squeezing margins. Comparable sales slowed in 2025 after years of strong growth. Despite leadership changes, Chipotle plans aggressive expansion, opening more than 4,000 locations with digital-enhanced Chipotlanes and global market entries in Mexico, South Korea, and Singapore set for 2026. Investors should weigh robust growth plans against near-term economic headwinds.
Go toTop